Back to Search
Start Over
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections.
- Source :
- Clinical Gastroenterology & Hepatology; Jan2021, Vol. 19 Issue 1, p195-195, 1p
- Publication Year :
- 2021
-
Abstract
- Hepatitis C virus infection is causing chronic liver disease, cirrhosis, and hepatocellular carcinoma. By combining direct-acting antivirals (DAAs), high sustained virologic response rates (SVRs) can be achieved. Resistance-associated substitutions (RASs) are commonly observed after DAA failure, and especially nonstructural protein 5A (NS5A) RASs may impact retreatment options.<superscript>1–3</superscript> Data on retreatment of DAA failure patients using first-generation DAAs are limited.<superscript>4–7</superscript> Recently, a second-generation protease- and NS5A-inhibitor plus sofosbuvir (voxilaprevir/velpatasvir/sofosbuvir [VOX/VEL/SOF]) was approved for retreatment after DAA failure.<superscript>8</superscript> However, this and other second-generation regimens are not available in many resource-limited countries or are not reimbursed by regular insurance, and recommendations regarding the selection of retreatment regimens using first-generation DAAs are very important. This study aimed to analyze patients who were re-treated with first-generation DAAs after failure of a DAA combination therapy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15423565
- Volume :
- 19
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Clinical Gastroenterology & Hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 147625136
- Full Text :
- https://doi.org/10.1016/j.cgh.2019.10.051